Stem Cell Therapeutics (SCT) is one of few public companies worldwide to focus exclusively on the development of stem cell technologies and the only public company concentrating on therapeutic stem cell development in Canada.

Founded on Dr. Sam Weiss’ seminal research from the Hotchkiss Brain Institute at the University of Calgary, we possess a pipeline of attractive clinical stage assets based on his work.

The significant leadership changes to the board and management that occurred in 2011 were designed to build upon our existing stem cell expertise. We have assembled a team of experts with significant experience in the areas of drug development and licensing. Building on Dr. Weiss’ work we will initially focus on leveraging the stem cell research output from Ontario because of the commitment in that province that is based on substantial provincial and national support. The new team plans to expand our portfolio by accessing development stage technologies from major universities and hospitals that are conducting leading-edge stem cell research, uniquely positioning SCT as the preferred receptor company for stem cell technologies from Canada and internationally.

As a stem cell technologies receptor company we act as a bridge to market for stem cell research. We propose to license and acquire additional technologies based on the original research of leading Canadian and international institutions, avoiding the risk inherent in basic research, and will advance the discoveries of others through the clinical and regulatory development process that converts research into actual products for the treatment of patients to restore function, replace cells and regenerate organs. We hold an exceptional position in the area of stem cell development permitting us to build value within Stem Cell Therapeutics by applying our expertise as recognized leaders in the biotechnology sector for the development of stem cell therapies to expand and advance our pipeline.